109 related articles for article (PubMed ID: 2131920)
1. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
[TBL] [Abstract][Full Text] [Related]
2. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
J Med; 1991; 22(3):145-56. PubMed ID: 1770322
[TBL] [Abstract][Full Text] [Related]
3. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
Nouts A; Lévy P; Voitot H; Bernades P
Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
[TBL] [Abstract][Full Text] [Related]
7. Serum carcinoembryonic antigen in the differential diagnosis of pancreatic cancer: influence of tumour spread, liver impairment, and age.
Basso D; Fabris C; Del Favero G; Angonese C; Meggiato T; Infantino A; Plebani M; Piccoli A; Leandro G; Burlina A
Dis Markers; 1988; 6(3):203-7. PubMed ID: 3168400
[TBL] [Abstract][Full Text] [Related]
8. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
Heptner G; Domschke S; Schneider MU; Domschke W
Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
[TBL] [Abstract][Full Text] [Related]
9. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
10. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A
Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
Collazos J; Genolla J; Ruibal A
Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
[TBL] [Abstract][Full Text] [Related]
12. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
16. Bile acid concentrations in the diagnosis of hepatobiliary disease in the cat.
Center SA; Baldwin BH; Erb H; Tennant BC
J Am Vet Med Assoc; 1986 Oct; 189(8):891-6. PubMed ID: 3771358
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
18. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
20. Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma.
Uehara M; Sato N
Hepatology; 1994 Aug; 20(2):326-30. PubMed ID: 8045492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]